The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 6, 1997, Pages 610-618

  Sica, Domenic A ^a   Marino, Maria R ^b   Hammert, Janice L ^b   Ferreira, Irene ^b   Gehr, Todd W B ^b   Ford, Neville F ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IRBESARTAN;

ARTERIAL PRESSURE; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE RESPONSE; DRUG TOLERANCE; ELECTROCARDIOGRAM; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; MAINTENANCE THERAPY; PRIORITY JOURNAL; VENOUS PRESSURE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BIPHENYL COMPOUNDS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RENAL DIALYSIS; TETRAZOLES;

EID: 0031408745     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90080-1     Document Type: Article

References (34)

1. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993;265:826-34.
2. 1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994; 251:143-50.
3. 1 receptor antagonist irbesartan in hypertension. Hypertension 1995;25:22-9.
4. Pool JL, Guthrie RM, Littlejohn T, Raskin P, Shepherd AMM, Weber MA, et al. The antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension [abstract]. Am J Hypertens 1996;9: 152A.
5. Marino MR, Langenbacher KM, Raymond RH, Whigan D, Ford NF. Pharmacokinetics (PK) and antihypertensive effects of irbesartan (an AII receptor antagonist) in subjects with hypertension [abstract]. J Hypertens 1996;14:S348.
6. Hagmann M, Burnier M, Nussberger J, Leenhardt AF, Brouard R, Waeber B, et al. Natriuretic and hormonal effects of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in normotensive volunteers [abstract]. Am J Hypertens 1994;7:13A.
7. Martinez F, Schmitt F, Savoiu C, Leenhardt AF, Brouard R, Peronnet P, et al. Effect of SR 47436 (BMS 186295) on renal hemodynamics and on glomerular permselectivity in healthy humans [abstract]. J Am Soc Nephrol 1994;5:607.
8. Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995;25(pt 1):602-9.
9. Sissmann J, Bouroudian M, Armagnac C, Donazollo Y, Latreille M, Panis R. Angiotensin II blockade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295) [abstract]. J Hypertens 1994;12:S92.
10. McIntyre M, MacFadyen RJ, Meredith PA, Brouard R, Reid JL. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. J Cardiovasc Pharmacol 1996;28: 101-6.
11. Marino MR, Langenbacher KM, Ford NF, Uderman HD. Safety, tolerability, pharmacokinetics and pharmacodynamics of irbesartan after single and multiple doses in healthy male subjects [abstract]. Clin Pharmacol Ther 1997;61:207.
12. Vachharajani N, Chang SY, Shyu WC, Greene D, Barbhaiya R. Absolute bioavailability of irbesartan, an angiotensin II receptor antagonist, in man [abstract]. Pharm Res 1995;12:S418.
13. Necciari J, Denolle T, Le Coz F, Donazollo Y, Pastor G, Sissmann J. Pharmacokinetics of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in man [abstract]. J Hypertens 1994;12:88.
14. Perrier L, Bourrié M, Marti E, Tronquet C, Massé D, Berger Y, et al. In vitro N-glucuronidation of SR 47436 (BMS 186295), a new ATI nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J Pharmacol Exp Ther 1994;271:91-9.
15. Vachharajani N, Shyu WC, Smith R, Chang SY, Greene D, Barbhaiya R. The effects of age and gender on the pharmacokinetics of irbesartan [abstract]. Pharm Res 1995;12:S388.
16. Farmen RH, Muniak JF, Pittman KA. Management of pharmacokinetic data using HP-3357/mainframe IBM interfacing. Drug Inf J 1987;21:141-53.
17. Chang SY, Whigan DB, Vachharajani NN, Patel R. A high-performance liquid chromatographic assay for quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urine. J Chromatogr 1997 [in press].
18. Brunner HR. ACE inhibitors in renal disease. Kidney Int 1992;12:463-79.
19. Sica DA. Kinetics of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992;20(suppl 10)S13-20.
20. Sica DA, Shaw WC, Lo MW, Keane WF, Gehr TWB, Halstenson CE, et al. The pharmacokinetics of losartan in renal insufficiency. J Hypertens 1995;13(suppl 1)S49-52.
21. Sica DA, Cutler RE, O'Connor DT, Ford NF. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril, and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet 1991;20:420-7.
22. Gibson TP. Renal disease and drug metabolism. Am J Kidney Dis 1986;8:7-17.
23. Anders MW. Metabolism of drugs by the kidney. Kidney Int 1980;18:636-47.
24. Sica DA, Comstock T, Harford AM, Eschelman F. Ranitidine kinetics in continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol 1987;32:587-91.
25. Lam FY, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997;32:30-57.
26. Ahmed JH, Grant AC, Rodger RSC. Inhibitory effect of uremia on the hepatic clearance and metabolism of nicardipine. Br J Clin Pharmacol 1991;32:57-72.
27. Erley CM, Bader B, Scheu M, Wolf S, Braun N, Risler T. Renal hemodynamics in essential hypertensives treated with losartan. Clin Nephrol 1995;43(suppl 1): S8-11.
28. Goldberg MR, Tunica W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993;21:704-13.
29. Delacrétaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995;25:14-21.
30. Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-21.
31. Ogihara T, Nagano M, Mikami H, Higaki J, Kohara K, Azuma J, et al. Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 1994;16:74-86.
32. Christen Y, Waeber B, Nussberger J, Lee RJ, Timmermans PBMWM, Brunner HR. Dose-response relationships following oral administration of DuP 753 to normal humans. Am J Hypertens 1991;4: 350S-3S.
33. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83:1333-42.
34. Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Laragh JH, Brenner BM, editors. Hypertension: Pathophysiology, diagnosis, and management. New York: Raven Press, 1990:1287-317.